• 1
    Kapp DS, Fischer D, Gutierrez E, Kohorn EI, Schwartz PE. Pretreatment prognostic factors in carcinoma of the uterine cervix: a multivariate analysis of the effect of age, stage, histology and blood counts on survival. Int J Radiat Oncol Biol Phys 1983; 9: 44555.
  • 2
    Bush RS, Jenkin RD, Allt WE, Beale FA, Bean H, Dembo AJ, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 1978; 37(Suppl III): 302–6.
  • 3
    Dische S, Anderson PJ, Sealy R, Watson ER. Carcinoma of the cervix-anaemia, radiotherapy and hyperbaric oxygen. Br J Radiol 1983; 56: 2515.
  • 4
    Evans J, Bergso P. The influence of anaemia on the results of radiotherapy in carcinoma of the cervix. Radiology 1965; 48: 70917.
  • 5
    Girinski T, Pejovic-Lenfant MH, Bourhis J, Campana F, Cosset JM, Petit C, et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 1989; 16: 3742.
  • 6
    Hierlihy P, Jenkin RD, Stryker JA. Anemia as a prognostic factor in cancer of the cervix: a preliminary report. Can Med Assoc J 1969; 100: 11002.
  • 7
    Schreiner P, Siracka E, Siracka J, Manka I. The effect of anemia on the radiotherapy results of the uterine cervix cancer. Neoplasma 1975; 22: 65560.
  • 8
    Vigario G, Kurohara SS, George FW. Association of hemoglobin levels before and during radiotherapy with prognosis in uterine cervix cancer. Radiology 1973; 106: 64952.
  • 9
    Bush RS. The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 1986; 12: 204750.
  • 10
    Dusenbery KE, McGuire WA, Holt PJ, Carson LF, Fowler JM, Twiggs LB, et al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 1994; 29(5): 107984.
  • 11
    Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 1992; 19: 2935.
  • 12
    Dische S, Hewitt HB. Carcinoma of the cervix with severe anaemia: treatment by radiotherapy without blood transfusion using hyperbaric oxygen. Br J Radiol 1972; 45: 84850.
  • 13
    Guichard M. The use of fluorocarbon emulsions in cancer radiotherapy. Radiother Oncol 1991; 20(Suppl): 5964.
  • 14
    Horseman MR, Chaplin DJ, Overgaard J. The use of blood flow modifiers to improve treatment response of solid tumors. Radiother Oncol 1991; 29(Suppl): 4752.
  • 15
    Martin DF, Porter E, Fischer JJ. Use of a perfluorochemical emulsion to improve the radiation response of BA 1112 rat sarcomas. Proc Radiat Res Soc 1985; 33: 142.
  • 16
    Vijayakumar S, Roach M, Wara W, Chan SK, Ewing C, Rubin S, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radical radiotherapy: preliminary results of a randomized, open-labeled, Phase II trial. Int J Radiat Oncol Biol Phys 1993; 26: 7219.
  • 17
    Hirst DG, Hazlehurst JL, Brown JM. The effect of alterations in hematocrit on tumor sensitivity to x-rays. Int J Radiat Oncol Biol Phys 1984; 46: 34554.
  • 18
    Hirst DG. Anemia: a problem or an opportunity in radiotherapy. Int J Radiat Oncol Biol Phys 1986; 12: 200917.
  • 19
    Poskitt T. Radiation therapy and the role of red blood cell transfusion. Cancer Invest 1987; 5: 2316.
  • 20
    Blumberg N, Agarwal MM, Chuang C. Relation between recurrence of cancer of the colon and blood transfusion. BMJ 1985; 290: 10379.
  • 21
    Blumberg N, Agarwal MM, Chuang C. A possible association between survival time and transfusion in cervical cancer. Yale J Biol Med 1988; 61: 493500.
  • 22
    Cummings PD, Wallace EL, Schorr JB, Dodd RY. Exposure of patients to human immunodeficiency virus through transfusion of blood components that test antibody-negative. N Engl J Med 1989; 321: 9416.
  • 23
    Donahue JG, Alvaro-Munoz DV, Ness PM, Brown DE, Nelson KE. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992; 327: 36973.
  • 24
    Busch O, Hop W, Hoynck van Papendrecht MA, Marquet RI, Jeekel J. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993;328: 13726.
  • 25
    Heiss M, Mempel W, Delanoff C, Jauch KW, Gabka C, Mempel M, et al. Blood transfusion modulated tumor recurrence—a randomized study of autologous blood transfusion in colorectal cancer. J Clin Oncol 1994; 12: 185967.
  • 26
    Burrows L, Tartter P. Effects of blood transfusion on the colonic malignancy recurrence rate. Lancet 1982; ii:662.
  • 27
    Tod M, Meredith W. Treatment of cancer of the cervix uteri—a revised Manchester Method. Br J Radiol 1953; 26: 2527.
  • 28
    Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187220.
  • 29
    Kaplan E, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 45781.
  • 30
    Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1979;35: 139.
  • 31
    Gehan E. A generalized Wilcoxon test for comparing arbitrarily single-censored samples. Biometrics 1965; 52(1,2): 203–23.
  • 32
    Hewitt HB, Blake E. Effect of induced host anaemia on the viability and radiosensitivity of murine malignant cells in vivo. Br J Cancer 1971; 25: 32336.
  • 33
    Hill RP, Bush RS, Yeung P. The effect of anaemia on the fraction of hypoxic cells in an experimental tumour. Br J Radiol 1971; 44: 299304.
  • 34
    Keys HM, Bundy BN, Stehman FB, et al. Weekly cisplatin chemotherapy during irradiation improves survival and reduces recurrences for patients with bulky Stage IB cervical cancer treated with irradiation and adjuvant hysterectomy: results of a randomized GOG trial (abstract 2). Society of Gynecologic Oncologists 29th annual meeting, February 711. Society of Gynecologic Oncologists, 1998.
  • 35
    Rose PG, Bundy B, Thigpen T, Deppe G, Maiman M, Clarke-Pearson D. Significant preliminary results of a Phase III randomized study of concomitant chemoradiation with hydroxyurea vs. hydroxyurea, 5-FU infusion and bolus cisplatin (HFC) vs. weekly cisplatin in advanced cervical cancer. A GOG study. Society of Gynecologic Oncologists, 1998.